ANDREA CASTILLO: Open Payments
NPI 1104476647 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,809 in 64 payments from 22 companies in 2025. Trend: 2023 $18 · 2024 $736 · 2025 $2,809
Food & beverage: $2,764Education: $45
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $500 |
| Lilly USA, LLC | 7 | $335 |
| ABBVIE INC. | 10 | $311 |
| Dexcom, Inc. | 5 | $306 |
| Amgen Inc. | 5 | $214 |
| Edwards Lifesciences Corporation | 2 | $203 |
| Novo Nordisk Inc | 4 | $190 |
| UCB, Inc. | 1 | $125 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $122 |
| ViiV Healthcare Company | 1 | $120 |
Products named: AIRSUPRA, QULIPTA, BREZTRI, SAPIEN 3 Ultra RESILIA, Dexcom G6 Transmitter, DEXCOM G7 GSS (161), Ozempic, Nayzilam.
Industry payments across NV — which companies pay providers there.
